STAT5-IN-3 

STAT5-IN-3 (Compound 14a) is a STAT5 inhibitor with anticancer activity. STAT5-IN-3 blocks the tyrosine phosphorylation of STAT5A/5B at the Y694/699 sites and significantly reduces the expression of STAT5B protein, thereby inhibiting downstream gene transcription and blocking the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 holds significant value in overcoming chemotherapy resistance^[1].

STAT5-IN-3 (Compound 14a) (100 nM-10 μM; 48 h) can inhibit the activity of myeloid leukemia cells (KU812, K562, KCL-22, MV-4-11, and MOLM-13) with EC₅₀ values of 0.6 μM, 0.8 μM, 0.5 μM, 0.3 μM, and 0.3 μM, respectively. In contrast, STAT5-IN-3 exhibits low toxicity towards normal cells (HS27A and MSC), with EC₅₀ values exceeding 10 μM for both cell types^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

413.51

C₂₅H₂₇N₅O

CC(CC1)(C)C2=C(C=CC=C2C3=CN=C(N)N=C3)N1CCOC4=CC=C5C(C=CN5)=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Polomski M, et al. Novel antileukemic compound with sub-micromolar potency against STAT5 addicted myeloid leukemia cells. Eur J Med Chem. 2025 Feb 15;284:117211.  [Content Brief]